Tahir Detinis Zur
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Tahir Detinis Zur has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Yuval Ebenstein
Department of Physical Chemistry, School of Chemistry, Tel Aviv University, Tel Aviv, Israel
2 shared publications - Ann-Kristin Afflerbach
Bioinformatics Core, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
1 shared publication Assaf Grunwald
School of Chemistry, Raymond and Beverly Sackler Faculty of Exact Sciences, Tel Aviv University, Tel Aviv 6997801, Israel
1 shared publication- Ben Meir Maoz
Sagol School of Neuroscience, Tel Aviv University, Tel Aviv 6997801, Israel
1 shared publication Jasline Deek
School of Chemistry, Center for Nanoscience and Nanotechnology, Center for Light-Matter Interaction, Raymond and Beverly Sackler Faculty of Exact Sciences, Tel Aviv University, Tel Aviv, Israel
1 shared publication- Jasline Deek
School of Chemistry, Raymond and Beverly Sackler Faculty of Exact Sciences, Tel Aviv University, Tel Aviv 6997801, Israel
1 shared publication
Latest Publications
- 11 January 2025
- Published by Elsevier in DNA Repair
- Vol. 146, 103808
Single-molecule toxicogenomics: Optical genome mapping of DNA-damage in nanochannel arrays
- 11 January 2025
- Published by Elsevier in DNA Repair
- Vol. 146, 103808
Single-molecule toxicogenomics: Optical genome mapping of DNA-damage in nanochannel arrays
- Open Access
- 5 July 2023
- Published by Elsevier in DNA Repair
- Vol. 129, 103533
Single-molecule approaches for DNA damage detection and repair: A focus on Repair Assisted Damage Detection (RADD)
- 5 July 2023
- Published by Elsevier in DNA Repair
- Vol. 129, 103533
Open AccessSingle-molecule approaches for DNA damage detection and repair: A focus on Repair Assisted Damage Detection (RADD)
- Open Access
- 10 September 2020
- Published by MDPI AG in Biomolecules
- Vol. 10 (9) , 1306
Mesenchymal Stem Cells as a Promising Cell Source for Integration in Novel In Vitro Models
The human-relevance of an in vitro model is dependent on two main factors—(i) an appropriate human cell source and (ii) a modeling platform that recapitulates human in vivo conditions. Recent years have brought substantial advancements in both these aspects. In particular, mesenchymal stem cells (MSCs) have emerged as a promising cell source, as these cells can differentiate into multiple cell types, yet do not raise the ethical and practical concerns associated with other types of stem cells. In turn, advanced bioengineered in vitro models such as microfluidics, Organs-on-a-Chip, scaffolds, bioprinting and organoids are bringing researchers ever closer to mimicking complex in vivo environments, thereby overcoming some of the limitations of traditional 2D cell cultures. This review covers each of these advancements separately and discusses how the integration of MSCs into novel in vitro platforms may contribute enormously to clinical and fundamental research.
- 10 September 2020
- Published by MDPI AG in Biomolecules
- Vol. 10 (9) , 1306
Open AccessMesenchymal Stem Cells as a Promising Cell Source for Integration in Novel In Vitro Models
The human-relevance of an in vitro model is dependent on two main factors—(i) an appropriate human cell source and (ii) a modeling platform that recapitulates human in vivo conditions. Recent years have brought substantial advancements in both these aspects. In particular, mesenchymal stem cells (MSCs) have emerged as a promising cell source, as these cells can differentiate into multiple cell types, yet do not raise the ethical and practical concerns associated with other types of stem cells. In turn, advanced bioengineered in vitro models such as microfluidics, Organs-on-a-Chip, scaffolds, bioprinting and organoids are bringing researchers ever closer to mimicking complex in vivo environments, thereby overcoming some of the limitations of traditional 2D cell cultures. This review covers each of these advancements separately and discusses how the integration of MSCs into novel in vitro platforms may contribute enormously to clinical and fundamental research.